SCHEMBL5565429

SCHEMBL5565429

Cn1c(CO)ccc1-c1nn(-c2ccccc2)c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.53
CNR2 P34972 2/20 0.40
ALDH1A1 P00352 7/20 0.39
KMT2A Q03164 1/20 0.39
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36
PDE3B Q13370 2/20 0.36
PDE3A Q14432 2/20 0.36
CNR1 P21554 1/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPT P10636 3/20 0.35
HPGD P15428 3/20 0.35
HSD17B10 Q99714 2/20 0.35
MAPK1 P28482 2/20 0.35
NPC1 O15118 1/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5557965 0.83 HTR2A (0.41) PDE5ACNR2PDE4APDE4BPDE4C
SCHEMBL5559742 0.82 PDE5A (0.55) PDE5ACNR2ALDH1A1PDE4APDE4B
SCHEMBL5564878 0.80 PDE5A (0.51) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5560123 0.80 PDE5A (0.51) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5563580 0.78 PDE5A (0.52) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5563794 0.78 PDE5A (0.52) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5557994 0.77 PDE5A (0.51) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5563632 0.75 PDE5A (0.52) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5563642 0.73 PDE5A (0.52) PDE5ACNR2ALDH1A1KMT2APDE4A
SCHEMBL5560882 0.72 PDE4A (0.45) PDE5ACNR2ALDH1A1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1842332-A Compounds, compositions and methods HIF BIO INC (US) 2006-10-04 CN claimed
EP-1646382-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO INC. (US) 2006-04-19 EP claimed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US claimed
WO-2005030121-A2 COMPOUNDS, COMPOSITIONS AND METHODS HIF BIO, INC. (US) 2005-04-07 WO claimed
US-7226941-B2 Compound for treating angiogenesis HIF BIO, INC. (US) 2007-06-05 US disclosed
US-7226941-B2 Compound for treating angiogenesis HIF BIO, INC. (US) 2007-06-05 US disclosed
US-20050187276-A1 Compounds, compositions and methods BIZBIOTECH CO., LTD. (KR) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187276-A1 Compounds, compositions and methods HIF1A, HIF1AN, EGLN3 PDE5A 1987/4885CNR2 915/4885ALDH1A1 858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.